Armata Pharmaceuticals

Company snapshot

Armas Pharmaceuticals is a generic pharmaceutical company delivering an ever-growing portfolio of high-quality products that provide convenience, affordability and consistency. Through the development of strong partnerships and industry relationships, Armas maintains this pipeline of products with customer and patient satisfaction in mind. Headquartered in Manalapan, New Jersey, Armas Pharmaceutic

• 9 active pipeline program(s) linked via ClinicalTrials.gov.
• 5 US patent(s) indexed to this assignee profile.
• 9 trial update(s) in the last 12 months.

Public regulatory, clinical, patent, and corporate records for Armata Pharmaceuticals. Not investment advice.

Recent activity

Latest pipeline, patent, and corporate events for Armata Pharmaceuticals.

1. May 23, 2026 Clinical update

   AP-PA02 — Phase 2

2. May 23, 2026 Clinical update

   AP-PA02 — Phase 2

3. May 23, 2026 Clinical update

   AP-SA02 — Phase 2

4. May 23, 2026 Clinical update

   C16G2 — Phase 2

5. May 23, 2026 Clinical update

   C16G2 Gel — Phase 2

View all clinical trial activity →

• What is Armata Pharmaceuticals?

  Armata Pharmaceuticals is a biotech organization headquartered in Freehold, USA. It trades on NYSE under ticker ARMP. Primary therapeutic focus areas include Dental Caries, Cystic Fibrosis, Non-cystic Fibrosis Bronchiectasis, Bacteremia. NovaPharmaNews links 9 clinical program(s)

• Is Armata Pharmaceuticals publicly traded?

  Yes. Armata Pharmaceuticals is listed with ticker ARMP on NYSE per SEC EDGAR records linked on this profile.

• What drugs does Armata Pharmaceuticals develop or market?

  No drug profiles are currently linked to Armata Pharmaceuticals. Pipeline programs may still list investigational assets.

• What are the latest developments for Armata Pharmaceuticals?

  In the last 12 months our linked public records show 9 trial program update(s) and 0 US patent grant(s) tied to this profile.

• What therapeutic areas does Armata Pharmaceuticals focus on?

  Armata Pharmaceuticals focuses on Dental Caries, Cystic Fibrosis, Non-cystic Fibrosis Bronchiectasis based on our analysis of their pipeline programs and drug development activities.